[HTML][HTML] Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti …

JN Kochenderfer, ME Dudley, SH Kassim… - Journal of clinical …, 2015 - ncbi.nlm.nih.gov
JN Kochenderfer, ME Dudley, SH Kassim, RPT Somerville, RO Carpenter…
Journal of clinical oncology, 2015ncbi.nlm.nih.gov
Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell
Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19
Chimeric Antigen Receptor - PMC Back to Top Skip to main content NIH NLM Logo Access
keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation Search PMC Full-Text
Archive Search in PMC Advanced Search User Guide Journal List J Clin Oncol
PMC4322257 Other Formats PubReader PDF (880K) Actions Cite Collections Share …
Abstract
Purpose
T cells can be genetically modified to express an anti-CD19 chimeric antigen receptor (CAR). We assessed the safety and efficacy of administering autologous anti-CD19 CAR T cells to patients with advanced CD19+ B-cell malignancies.
ncbi.nlm.nih.gov